| 13.4 -0.45 (-3.25%) | 08-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.86  |
1-year : | 19.69 |
| Resists | First : | 14.43 |
Second : | 16.86 |
| Pivot price | 12.06 |
|||
| Supports | First : | 11.19 |
Second : | 9.18 |
| MAs | MA(5) : | 13.22 |
MA(20) : | 11.68 |
| MA(100) : | 8.79 |
MA(250) : | 5.26 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 85.9 |
D(3) : | 90.1 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 15.88 | Low : | 1.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SLS ] has closed below upper band by 16.4%. Bollinger Bands are 9.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.45 - 14.52 | 14.52 - 14.57 |
| Low: | 12.86 - 12.95 | 12.95 - 13.01 |
| Close: | 13.27 - 13.41 | 13.41 - 13.5 |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Fri, 21 Aug 2026
SELLAS Life Sciences Group (SLS) Shares Just Moved, So What Is Drawing Attention? - Yahoo Finance
Fri, 21 Aug 2026
SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress - Yahoo Finance
Thu, 20 Aug 2026
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
Thu, 20 Aug 2026
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
Thu, 20 Aug 2026
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Wed, 19 Aug 2026
SELLAS Life Sciences Group (SLS) Nears Key Phase 3 Readout On A Pricey Valuation - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 197 (M) |
| Shares Float | 185 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 32 (%) |
| Shares Short | 55,280 (K) |
| Shares Short P.Month | 63,360 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | -43.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -58.27 |
| PEG Ratio | 0 |
| Price to Book value | 22.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -93.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|